43 found
Order:
  1.  35
    Blueprint for Transparency at the U.S. Food and Drug Administration: Recommendations to Advance the Development of Safe and Effective Medical Products.Joshua M. Sharfstein, James Dabney Miller, Anna L. Davis, Joseph S. Ross, Margaret E. McCarthy, Brian Smith, Anam Chaudhry, G. Caleb Alexander & Aaron S. Kesselheim - 2017 - Journal of Law, Medicine and Ethics 45 (s2):7-23.
    BackgroundThe U.S. Food and Drug Administration traditionally has kept confidential significant amounts of information relevant to the approval or non-approval of specific drugs, devices, and biologics and about the regulatory status of such medical products in FDA’s pipeline.ObjectiveTo develop practical recommendations for FDA to improve its transparency to the public that FDA could implement by rulemaking or other regulatory processes without further congressional authorization. These recommendations would build on the work of FDA’s Transparency Task Force in 2010.MethodsIn 2016-2017, we convened (...)
    No categories
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   5 citations  
  2.  14
    Effect of Financial Relationships on the Behaviors of Health Care Professionals: A Review of the Evidence. [REVIEW]Christopher Robertson, Susannah Rose & Aaron S. Kesselheim - 2012 - Journal of Law, Medicine and Ethics 40 (3):452-466.
    Physicians, scholars, and policymakers continue to be concerned about conflicts of interests among health care providers. At least two main types of objections to conflicts of interest exist. Conflicts of interests may be intrinsically troublesome if they violate providers’ fiduciary duties to their patients or they contribute to loss of trust in health care professionals and the health care system. Conflicts of interest may also be problematic in practice if they bias the decisions made by providers, adversely impacting patient outcomes (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   13 citations  
  3.  18
    Challenges and Opportunities for Biomarker Validation.Spencer Phillips Hey, Elvira D'Andrea, Emily H. Jung, Frazer Tessema, Jing Luo, Bishal Gyawali & Aaron S. Kesselheim - 2019 - Journal of Law, Medicine and Ethics 47 (3):357-361.
    Biomarkers can be powerful tools to guide diagnosis, treatment, and research. However, prudent use of biomarkers requires formal validation efforts. Although the data needed for biomarker validation has traditionally been hard to access, new research initiatives can ease this process.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  4.  36
    Insights From a National Conference: “Conflicts of Interest in the Practice of Medicine”.Aaron S. Kesselheim & David Orentlicher - 2012 - Journal of Law, Medicine and Ethics 40 (3):436-440.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  5.  41
    The Ethics of Intellectual Property Rights in an Era of Globalization.Aakash Kaushik Shah, Jonathan Warsh & Aaron S. Kesselheim - 2013 - Journal of Law, Medicine and Ethics 41 (4):841-851.
    Since the 1980s, developed countries, led by the United States and the countries of the European Union, have sought to incorporate intellectual property rights provisions into global trade agreements. These countries successfully negotiated the World Trade Organization's 1994 Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which required developing countries to adopt intellectual property provisions comparable to developed countries. In this manuscript, we review the policy controversy surrounding TRIPS and examine the two main ethical arguments articulated in its support (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  6.  28
    The Ethics of Intellectual Property Rights in an Era of Globalization.Aakash Kaushik Shah, Jonathan Warsh & Aaron S. Kesselheim - 2013 - Journal of Law, Medicine and Ethics 41 (4):841-851.
    In recent decades, advances in information technology have given rise to a post-industrial society in which emphasis on the manufacture of material goods has been supplanted by the creation of intellectual property. Indeed, this new “knowledge economy” can be tracked by the exponential growth in patented products across a range of sectors since the 1980s. According to the United States Patent and Trademark Office, the number of annual patent applications submitted grew from 112,379 to 520,277 over the past three decades, (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  7.  12
    Patients' Knowledge of Key Messaging in Drug Safety Communications for Zolpidem and Eszopiclone: A National Survey.Aaron S. Kesselheim, Michael S. Sinha, Paula Rausch, Zhigang Lu, Frazer A. Tessema, Brian M. Lappin, Esther H. Zhou, Gerald J. Dal Pan, Lee Zwanziger, Amy Ramanadham, Anita Loughlin, Cheryl Enger, Jerry Avorn & Eric G. Campbell - 2019 - Journal of Law, Medicine and Ethics 47 (3):430-441.
    Drug Safety Communications are used by the Food and Drug Administration to inform health care providers, patients, caregivers, and the general public about safety issues related to FDA-approved drugs. To assess patient knowledge of the messaging contained in DSCs related to the sleep aids zolpidem and eszopiclone, we conducted a large, cross-sectional patient survey of 1,982 commercially insured patients selected by stratified random sampling from the Optum Research Database who had filled at least two prescriptions for either zolpidem or eszopiclone (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  8.  4
    Surrogate Endpoints and Drug Regulation: What Is Needed to Clarify the Evidence.Spencer Phillips Hey, William B. Feldman, Emily H. Jung, Elvira D'Andrea & Aaron S. Kesselheim - 2019 - Journal of Law, Medicine and Ethics 47 (3):381-387.
    The FDA's new table of surrogate endpoints used for drug approvals is an important step forward for overseeing the use of biomarkers in clinical trials. Nevertheless, we present several ways in which the table can be improved.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  9.  8
    Can Outcomes-Based Pharmaceutical Contracts Reduce Drug Prices in the US? A Mixed Methods Assessment.Elizabeth Seeley, Susan Chimonas & Aaron S. Kesselheim - 2018 - Journal of Law, Medicine and Ethics 46 (4):952-963.
    To improve the value of pharmaceutical spending, some manufacturers and payers have introduced outcomes-based contracts, where rebates are tied to specified outcomes. We reviewed the literature and interviewed key experts to assess these contracts' potential to slow pharmaceutical spending. We found that while outcomes-based contracts are increasingly common in the US, they are still limited by multiple factors — including the lack of meaningful outcomes data. Moreover, there is no evidence to date that they slow pharmaceutical spending or increase access. (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  10.  23
    The Effects of the Sunshine Act: What Can and Should We Expect?Michael S. Sinha & Aaron S. Kesselheim - 2017 - American Journal of Bioethics 17 (6):22-24.
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  11.  19
    The Real‐World Ethics of Adaptive‐Design Clinical Trials.Laura E. Bothwell & Aaron S. Kesselheim - 2017 - Hastings Center Report 47 (6):27-37.
    From the earliest application of modern randomized controlled trials in medical research, scientists and observers have deliberated the ethics of randomly allocating study participants to trial control arms. Adaptive RCT designs have been promoted as ethically advantageous over conventional RCTs because they reduce the allocation of subjects to what appear to be inferior treatments. Critical assessment of this claim is important, as adaptive designs are changing medical research, with the potential to significantly shift how clinical trials are conducted. Policy-makers are (...)
    Direct download  
     
    Export citation  
     
    Bookmark   1 citation  
  12.  14
    Using Patent Data to Assess the Value of Pharmaceutical Innovation.Aaron S. Kesselheim & Jerry Avorn - 2009 - Journal of Law, Medicine and Ethics 37 (2):176-183.
    Only 19 new molecular entities and 3 biologics were approved by the Food and Drug Administration in 2007, the lowest rate in 24 years. This disappointing output occurred despite steady clinical trial and regulatory review times, the FDA maintaining high approval rates, and the pharmaceutical industry consistently reporting increasing revenues. A government report suggests that fewer new drug applications have been submitted to the FDA by the pharmaceutical industry in recent years. These data have rekindled the debate as to the (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  13.  17
    Reprioritizing Research Activity for the Post‐Antibiotic Era: Ethical, Legal, and Social Considerations.Spencer Phillips Hey & Aaron S. Kesselheim - 2017 - Hastings Center Report 47 (2):16-20.
    Many hold that the so-called golden era of antibiotic discovery has passed, leaving only a limited clinical pipeline for new antibiotics. A logical conclusion of such arguments is that we need to reform the current system of antibiotic drug research—including clinical trials and regulatory requirements—to spur activity in discovery and development. The United States Congress in the past few years has debated a number of bills to address this crisis, including the 2012 Generating Antibiotic Incentives Now Act and the 2016 (...)
    Direct download  
     
    Export citation  
     
    Bookmark   1 citation  
  14.  13
    Introduction.Anna L. Davis, James Dabney Miller, Joshua M. Sharfstein & Aaron S. Kesselheim - 2017 - Journal of Law, Medicine and Ethics 45 (s2):5-6.
    No categories
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  15.  18
    Using Patent Data to Assess the Value of Pharmaceutical Innovation.Aaron S. Kesselheim & Jerry Avorn - 2009 - Journal of Law, Medicine and Ethics 37 (2):176-183.
    Though many more patents emerge from industry sources, drug-related patents generated in the non-profit setting appear to have greater importance than patents arising from the commercial sector, which helps demonstrate the value non-profit research institutions can have in driving drug development.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  16.  33
    Approval and Withdrawal of New Antibiotics and Other Antiinfectives in the U.S., 1980–2009.Kevin Outterson, John H. Powers, Enrique Seoane-Vazquez, Rosa Rodriguez-Monguio & Aaron S. Kesselheim - 2013 - Journal of Law, Medicine and Ethics 41 (3):688-696.
    Numerous reports have noted decreasing numbers of antibiotic approvals. To determine the context for this decline, we examined all new molecule entities (NMEs) and new biologic licenses (NBLs) approved by the FDA from 1980–2009, and compared approval rates of the 61 approved antibiotics to trends in other drug classes. We also tracked withdrawals of approved drugs and found more withdrawals for antibiotics than other drug classes. After adjusting for drugs subsequently withdrawn, the record for antibiotic innovation is less dire than (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  17.  19
    Approval and Withdrawal of New Antibiotics and Other Antiinfectives in the U.S., 1980–2009.Kevin Outterson, John H. Powers, Enrique Seoane-Vazquez, Rosa Rodriguez-Monguio & Aaron S. Kesselheim - 2013 - Journal of Law, Medicine and Ethics 41 (3):688-696.
    Antibiotic use triggers evolutionary and ecological responses from bacteria, leading to antibiotic resistance and harmful patient outcomes. Two complementary strategies support long-term antibiotic effectiveness: conservation of existing therapies and production of novel antibiotics. Conservation encompasses infection control, antibiotic stewardship, and other public health interventions to prevent infection, which reduce antibiotic demand. Production of new antibiotics allows physicians to replace existing drugs rendered less effective by resistance.In recent years, physicians and policymakers have raised concerns about the pipeline for new antibiotics, pointing (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  18.  3
    Research Ethics for Emerging Trial Designs: Does Equipoise Need to Adapt?Spencer Phillips Hey, Charles Weijer, Monica Taljaard & Aaron S. Kesselheim - 2018 - Bmj 360.
    Key messages The research environment has changed since clinical equipoise was first proposed 30 years ago New trial designs—such as umbrella and basket trials, adaptive platform trials, and cluster randomised trials—raise new ethical challenges for evaluating the state of scientific uncertainty and communicating about risks with patients and participants Clinical equipoise needs to evolve We propose the design of specific guidelines to provide ethics committees and trialists with instructions for how to evaluate equipoise in the context of new designs and (...)
    No categories
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  19.  18
    Using Malpractice Claims to Identify Risk Factors for Neurological Impairment Among Infants Following Non‐Reassuring Fetal Heart Rate Patterns During Labour.Aaron S. Kesselheim, Martin T. November, Karen L. Lifford, Thomas F. McElrath, Ann L. Puopolo, E. John Orav & David M. Studdert - 2010 - Journal of Evaluation in Clinical Practice 16 (3):476-483.
  20.  36
    Evidence, Errors, and Ethics.Franklin G. Miller, Steven Joffe & Aaron S. Kesselheim - 2014 - Perspectives in Biology and Medicine 57 (3):299-307.
    Novel therapeutics enter human testing after they show promise in animal and in vitro studies. They then begin a life cycle that extends from early phase trials without control groups, to randomized trials, to approval by regulatory authorities, to coverage by payers, to use in clinical practice. At each stage, scientific evidence is critical to determining whether to progress to the next step in this life cycle. Each of these decisions also implicitly involves issues of value and ethical norms based (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  21.  35
    Medical Innovation Then and Now: Perspectives of Innovators Responsible for Transformative Drugs.Shuai Xu & Aaron S. Kesselheim - 2014 - Journal of Law, Medicine and Ethics 42 (4):564-575.
    Effective medical innovation is a common goal of policymakers, physicians, researchers, and patients both in the private and public sectors. With the recent slowdown in approval of new transformative prescription drugs, many have looked back to the “golden years” of the 1980s and 1990s when numerous breakthrough products emerged. We conducted a qualitative study of innovators directly involved in creation of groundbreaking drugs during that era to determine what made their work successful and how the process of conducting medical innovation (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  22. Over-the-Counter Monograph Safety, Innovation, and Reform Act.Jason Gardiner & Aaron S. Kesselheim - 2021 - Journal of Law, Medicine and Ethics 49 (2):321-327.
    Over-the-counter drugs are ubiquitous in the US. Policymakers have long debated how to modernize the system for making determinations of safety and effectiveness and addressing safety issues with OTC drugs.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  23. Limitations on the Capability of the FDA to Advise.Aaron S. Kesselheim & Leah Z. Rand - 2022 - American Journal of Bioethics 22 (10):15-17.
    Svirsky, Howard, and Berman address the U.S. Food and Drug Administration ’s oversight of tobacco products, the newest major area of regulation Congress assigned to the FDA. They discus...
    No categories
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  24. The Supreme Court's Latest Ruling on Drug Liability and its Implications for Future Failure-to-Warn Litigation.Christopher J. Morten, Aaron S. Kesselheim & Joseph S. Ross - 2019 - Journal of Law, Medicine and Ethics 47 (4):783-787.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  25. An International Review of Health Technology Assessment Approaches to Prescription Drugs and Their Ethical Principles.Leah Z. Rand & Aaron S. Kesselheim - 2020 - Journal of Law, Medicine and Ethics 48 (3):583-594.
    In many countries, health technology assessment organizations determine the economic value of new drugs and make recommendations regarding appropriate pricing and coverage in national health systems. In the US, recent policy proposals aimed at reducing drug costs would link drug prices to six countries: Australia, Canada, France, Germany, Japan, and the UK. We reviewed these countries’ methods of HTA and guidance on price and coverage recommendations, analyzing methods and guidance documents for differences in the methodologies HTA organizations use to conduct (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  26. High-Priced Sickle Cell Gene Therapies Threaten to Exacerbate US Health Disparities and Establish New Pricing Precedents for Molecular Medicine.Frazer A. Tessema, Ameet Sarpatwari, Leah Z. Rand & Aaron S. Kesselheim - 2022 - Journal of Law, Medicine and Ethics 50 (2):380-384.
    Gene therapies to treat sickle cell disease are in development and are expected to have high costs. The large eligible population size — by far, the largest for a gene therapy — poses daunting budget challenges and threatens to exacerbate health disparities for Black patients, who make up the vast majority of American sickle cell patients.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  27.  8
    Implementing U.S. Covid-19 Testing: Regulatory and Infrastructural Challenges.Yongtian Tina Tan & Aaron S. Kesselheim - 2020 - Journal of Law, Medicine and Ethics 48 (3):608-612.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  28.  11
    Approximating Future Generic Entry for New Drugs.Reed F. Beall, Jonathan J. Darrow & Aaron S. Kesselheim - 2019 - Journal of Law, Medicine and Ethics 47 (1):177-182.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  29.  10
    Orphan Drug Designation and Exclusivity for “Same Drugs”.Phebe Hong, Ameet Sarpatwari & Aaron S. Kesselheim - 2019 - Journal of Law, Medicine and Ethics 47 (2):347-349.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  30.  32
    Ethical Issues in New Drug Prescribing.Lindsay W. Cole, Jennifer C. Kesselheim & Aaron S. Kesselheim - 2012 - Journal of Bioethical Inquiry 9 (1):77-83.
    We use the format of a hypothetical case study to review issues related to pharmaceutical product approval and physician prescribing practices. In this case, a new FDA-approved drug is recommended for a patient who subsequently experiences an adverse event that may or may not be related to the prescription. This case raises a number of ethical and legal considerations physicians routinely face when deciding whether to recommend such drugs for their patients. Despite the need for ongoing observation by the regulatory (...)
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark  
  31.  12
    Government Patent Use to Address the Rising Cost of Naloxone: 28 U.S.C. § 1498 and Evzio.Alex Wang & Aaron S. Kesselheim - 2018 - Journal of Law, Medicine and Ethics 46 (2):472-484.
    The rising cost of the opioid antagonist and overdose reversal agent naloxone is an urgent public health problem. The recent and dramatic price increase of Evzio, a naloxone auto-injector produced by Kaléo, shows how pharmaceutical manufacturers entering the naloxone marketplace rely on market exclusivity guaranteed by the patent system to charge prices at what the market can bear, which can restrict access to life-saving medication. We argue that 28 U.S.C. § 1498, a section of the federal code that allows the (...)
    No categories
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  32.  13
    Public Participation in Drafting of the 21st Century Cures Act.Thomas J. Hwang, Rachel E. Sachs & Aaron S. Kesselheim - 2017 - Journal of Law, Medicine and Ethics 45 (2):212-220.
    The 21st Century Cures Act is a major act of legislation that contains numerous changes to drug and device regulation. The House of Representatives passed the Act after considerable interest group lobbying, but the bill and the key changes made during its drafting remain controversial. Using publicly disclosed records of written comments on the bill, we reviewed the key areas of lobbying activity and the compromises made in the final text. We focused on legislative provisions relating to management of the (...)
    No categories
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  33.  11
    Defining “True and Non-Misleading” for Pharmaceutical Promotion.Spencer Phillips Hey & Aaron S. Kesselheim - 2018 - Journal of Law, Medicine and Ethics 46 (2):552-554.
    No categories
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  34.  18
    Medical Innovation Then and Now: Perspectives of Innovators Responsible for Transformative Drugs.Shuai Xu & Aaron S. Kesselheim - 2014 - Journal of Law, Medicine and Ethics 42 (4):564-575.
    The discovery and development of new therapeutics has always been central to improving health worldwide. However, there is ongoing concern regarding the current state of medical innovation. Output from the pharmaceutical industry has been criticized for not being “transformative,” that is, offering substantial improvements in patient outcomes over existing therapeutics. While the cost of drug development continues to rise, breakthrough therapies remain elusive and one half of Phase 3 studies fail. Venture capital, a traditional source of funding for new breakthrough (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  35.  26
    Conflicts of Interest and the Future of Medicine: The United States, France, and Japan: Marc A. Rodwin, 2011, Oxford University Press. [REVIEW]Adam Licurse & Aaron S. Kesselheim - 2011 - Journal of Bioethical Inquiry 8 (4):383-386.
    Conflicts of Interest and the Future of Medicine: The United States, France, and Japan Content Type Journal Article Category Book Review Pages 383-386 DOI 10.1007/s11673-011-9326-y Authors Adam Licurse, Division of Internal Medicine, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA Aaron S. Kesselheim, Harvard Medical School, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, 1620 Tremont St. Suite 3030, Boston, MA, USA Journal Journal of Bioethical Inquiry Online ISSN 1872-4353 Print ISSN 1176-7529 Journal Volume (...)
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark  
  36.  4
    Development of a National Public Pharmaceutical Research and Development Institute.Ameet Sarpatwari, Dana Brown & Aaron S. Kesselheim - 2020 - Journal of Law, Medicine and Ethics 48 (1):225-227.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  37.  4
    Characteristics of Clinical Trials Launched Early in the COVID-19 Pandemic in the US and in France.Véronique Raimond, Julien Mousquès, Jerry Avorn & Aaron S. Kesselheim - 2021 - Journal of Law, Medicine and Ethics 49 (1):139-151.
    Based on hierarchical classification and logistic regression of early US and French COVID-19 clinical trials we show that despite the registration of a large number of trials, only a minority had characteristics usually associated with providing robust and relevant evidence.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  38.  5
    The Tax Cuts and Jobs Act of 2017 and the Pharmaceutical Industry.Michael S. Sinha & Aaron S. Kesselheim - 2018 - Journal of Law, Medicine and Ethics 46 (3):806-808.
  39.  2
    Generic Competition for Drugs Treating Rare Diseases.Reed F. Beall, Amity E. Quinn, Aaron S. Kesselheim, Frazer A. Tessema & Ameet Sarpatwari - 2020 - Journal of Law, Medicine and Ethics 48 (4):789-795.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  40.  2
    Origins and Ownership of Remdesivir: Implications for Pricing.ChangWon C. Lee, Jonathan J. Darrow, Jerry Avorn & Aaron S. Kesselheim - 2020 - Journal of Law, Medicine and Ethics 48 (3):613-618.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  41.  1
    Promoting Competition in Drug Pricing: A Review of Recent Congressional Legislation. [REVIEW]Sarosh Nagar & Aaron S. Kesselheim - 2021 - Journal of Law, Medicine and Ethics 49 (4):683-687.
    Brand-name prescription drug manufacturers use various strategies to extend their market exclusivity periods by delaying generic or biosimilar competition. Recent Congressional legislation has targeted four such tactics. We analyze these proposals and assess their likely effect on competition in the U.S. drug market.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  42.  3
    INTRODUCTION: Public Sector and Non-Profit Contributions to Drug Development — Historical Scope, Opportunities, and Challenges.Ameet Sarpatwari & Aaron S. Kesselheim - 2021 - Journal of Law, Medicine and Ethics 49 (1):6-9.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  43.  1
    Lung Cancer Survival Gains: Contributions of Academia and Industry.Bishal Gyawali, Gauthier Bouche, Pan Pantziarka, Aaron S. Kesselheim & Ameet Sarpatwari - 2019 - Journal of Law, Medicine and Ethics 47 (3):465-467.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark